The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1511
ISSUE 1511
January 2, 2017
Another Insulin Glargine (Basaglar) for Diabetes
| The full article is available to subscribers | Subscriber Login |
January 2, 2017 (Issue: 1511)
Revised 1/20/17: In the Dosage and Administration paragraph, we removed the word "syringe" in describing Basaglar's KwikPen device. Basaglar is not available as a prefilled syringe; it is only available as a KwikPen.
The FDA has approved Basaglar (Lilly/Boehringer Ingelheim), a "follow-on" 100 units/mL insulin glargine product similar to Lantus (Sanofi), which recently went off patent. A 300 units/mL formulation of insulin glargine (Toujeo) was approved in 2015.1
INSULIN GLARGINE — A recombinant DNA analog of human insulin, insulin glargine forms microprecipitates in subcutaneous tissue, prolonging its duration of action to a mean of about 24 hours.2 It has less peak-to-trough variation and causes less nocturnal hypoglycemia than NPH insulin.
CLINICAL STUDIES — Approval of Basaglar was based on data demonstrating the clinical efficacy and safety of Lantus.3 Comparative studies have found no significant differences in the pharmacokinetics, toxicity,
... more- Concentrated insulin glargine (Toujeo) for diabetes. Med Lett Drugs Ther 2015; 57:69.
- Drugs for diabetes. Med Lett Drugs Ther 2017; 59:9.
- Center for Drug Evaluation and Research. Basaglar Summary Review. Available at: www.accessdata.fda.gov. Accessed December 20, 2016.
- H Linnebjerg et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care 2015; 38:2226.
- LL Ilag et al. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus insulin glargine in patients with type 1 or type 2 diabetes mellitus. Diabetes Obes Metab 2016; 18:159.
- TC Blevins et al. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab 2015; 17:726.
- J Rosenstock et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab 2015; 17:734.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Another Insulin Glargine (Basaglar) for Diabetes
Article code: 1511b
Electronic, downloadable article - $45
Article code: 1511b
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
